medRxiv preprint doi: https://doi.org/10.1101/2022.12.20.22283748; this version posted December 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

1 Impact of a multi-disease integrated screening and diagnostic model for COVID-19, TB, and HIV in Lesotho 2

3 4

Bulemba Katende¹, Moniek Bresser^{2,3}, Mashaete Kamele¹, Lebohang Chere⁴, Mosa Tlahali⁵, 5 Rahel Milena Erhardt^{2,3}, Josephine Muhairwe¹, Irene Ayakaka¹, Tracy R Glass^{2,3}, Morten 6 Ruhwald⁶, Bram van Ginneken⁷, Keelin Murphy⁷, Margaretha de Vos⁸, Alain Amstutz⁹, 7 Mathabo Mareka¹⁰, Sekhele Matabo Mooko¹⁰, Niklaus D. Labhardt^{2,3,8}, Klaus Reither^{2,3}, Lucia 8 9 González Fernández^{2,3,8,11}

10

Authors Affiliation: 11

- ¹ SolidarMed, Partnerships for Health, Maseru, Lesotho 12
- 13 ² Swiss Tropical and Public Health Institute, Allschwil, Switzerland
- ³ University of Basel, Basel, Switzerland 14
- ⁴ Butha-Buthe District Health Management Team, Butha-Buthe, Lesotho 15
- ⁵ Mokhotlong District Health Management Team, Mokhotlong, Lesotho 16
- ⁶ FIND, the global alliance for diagnostics, Geneva, Switzerland 17
- ⁷ Diagnostic Image Analysis Group, Radboud UMC, Niimegen, The Netherlands 18
- 19 ⁸ Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland 20
- 21 ⁹CLEAR Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 22
- 23 ¹⁰ National Reference Laboratory, Ministry of Health of Lesotho, Maseru
- ¹¹ SolidarMed, Partnerships for Health, Lucerne, Switzerland 24
- 25
- **Correspondence to:** 26

27 Klaus Reither: klaus.reither@swisstph.ch

- 28
- Keywords: SARS-CoV-2, COVID-19, HIV, Tuberculosis, integrated TB/COVID-19, sub-29 Saharan Africa, Lesotho 30
- 31
- 32
- 33
- 34
- 35
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 36

37 Abstract 298 words

38 Introduction

The surge of the COVID-19 pandemic challenged health services globally, and in Lesotho, the HIV and tuberculosis (TB) services were similarly affected. Integrated, multi-disease diagnostic services were proposed solutions to mitigate these disruptions. We describe and evaluate the effect of an integrated, hospital-based COVID-19, TB and HIV screening and diagnostic model in two rural districts in Lesotho, during the period between December 2020 and August 2022.

45 Methods

Adults and children above 5 years attending two hospitals were screened for COVID-19 and TB symptoms. After a positive screening, participants were offered to enroll in a service model that included clinical evaluation, chest radiography, SARS-CoV-2, Xpert MTB/RIF Ultra and HIV testing. Participants diagnosed with COVID-19, TB, or HIV were contacted after 28 days evaluate their health status, and linkage to HIV or TB services.

51 Results

Of the 179160 participants screened, 6623(37%) screened positive, and 4371(66%) were 52 enrolled in this service model, yielding a total of 458 diagnoses. One positive rapid antigen 53 test for SARS-CoV-2 was found per 11 participants screened, one Xpert-positive TB case was 54 diagnosed per 85 people screened, and 1 new HIV diagnosis was done per 182 people 55 screened. Of the 321(82.9%) participants contacted after 28 days of diagnosis, 304(94.7%) 56 reported to be healthy. Of the individuals that were newly diagnosed with HIV or TB, 57 18/24(75.0%) and 46/51(90.1%) started treatment. This service showed no difference in the 58 detection of new HIV and TB cases when compared to other hospitals, where no such 59 integrated service model was provided. 60

61 Conclusion

This screening and diagnostic model successfully maintained same-day, integrated COVID-19, TB, and HIV testing services through different COVID-19 incidence periods in a resourcelimited context. There were positive effects in avoiding diagnostic delays and ensuring linkage to services, however, efficiencies were contingent on the successful adaptation to the changing environment.

67

68 Introduction

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the 69 coronavirus disease 2019 (COVID-19) pandemic negatively impacted health services delivery 70 in most countries, even where health systems were thought to be well-established(1-4). At 71 the same time that the pandemic created a significant increase in morbidity and mortality 72 globally, health facilities across the globe shut down or restricted their activity to the provision 73 of essential services. Factors such as infection control risks, lack of health workers or personal 74 75 protective equipment(5) led to a substantial reduction in access to primary health care worldwide(6). In countries with high TB and HIV prevalence, the COVID-19 pandemic reversed 76 years of progress in the control of these $2 \mod(7,8)$. 77

78 Although the African continent reported relatively low COVID-19 cases, compared to other 79 regions in the world, the impact of the pandemic on health service delivery was still very 80 significant. Access to health facility-based services was interrupted as a result of 1) health workers shortages due to illness, self-quarantine, or strikes, 2) health facilities repurposed for 81 82 COVID-19 treatment, covering minimum services, or closed completely, and 3) clients' reluctance to attend to visits, due to fear of increased risk of COVID-19 exposure, or 83 84 decreased availability of public transportation(6,9,10). A review by Gizachew A. Tessema et al. reported substantial reduction in access to essential and general health services across 85 the African continent(11), and in South Africa, a study in the KwaZulu Natal province reported 86

an estimated 47.6% and 46.2% decrease in HIV testing and anti-retroviral therapy initiation
respectively(12).

Lesotho is a country in the sub-Saharan region with over 2 million population(13). The 89 90 estimated TB incidence sits at 614%, the HIV prevalence is 20.9%, and there is approximately 55% TB/HIV coinfection(14–16). Similar to other settings, the health system and health 91 services in Lesotho were similarly affected by the COVID-19 pandemic(17-21). The first 92 COVID-19 case was reported in May 2020, and up to December 2022, approximately 34,490 93 COVID-19 cases and 706 COVID-19 related deaths have been reported. Although cases have 94 95 been recorded continuously since May 2020, three significant waves were described, with high incident rates in December 2020, June to September 2021, and December 2021(22). To 96 reinforce the efforts against the spread of SARS-CoV-2, the government of Lesotho set up a 97 public health strategy that regulated social norms to ensure physical distance between people. 98 99 A COVID-19 Risk Determination and Mitigation Framework was created as a 5-colour scale. regulating daily life activities, depending on the COVID-19 reproductive number (R0) 100 101 determined regularly. The scale of colors varied from green, blue, purple, yellow, and red. Green color was associated with R0 < 1 and red color was associated with R0 > 2.5. Typically, 102 103 at each subsequent level, social measures became more stringent, and included mandates, such as staying home, avoiding crowds, or closure of business and borders (23-28). 104

In this context, the project named Mitigation strategies for communities with COVID-19 in 105 Lesotho -MistraL-(29) was conceived as an initiative to expand COVID-19 diagnosis and 106 integrate TB and HIV testing in the districts of Butha-Buthe and Mokhotlong, situated in the 107 108 northeast part of the country (figure 1). From December 2020 to August 2022, MistraL reinforced the health system response (table 1), contributing to aspects such as: 1) support to 109 the COVID-19 response coordination at district and national level: 2) addition of resources to 110 111 improce health facilities infrastructure and provision of medical equipment; 3) integration of 112 COVID-19/TB/HIV testing and linkage model; 4) addition and training of health workers for 113 provision of services; and 5) implementation of research activities, including SARS-CoV-2

114 RTT tests validation in nasopharyngeal and nasal samples, or use and validation a of 115 computer- aided diagnostic software for COVID-19 (CAD4COVID).

In recent years, there has been an increasing interest to understand whether and how 116 integrated screening and testing services could provide access to prompt COVID-19 diagnosis 117 and management, while maintaining diagnostic and linkage services for TB and HIV, in an 118 epidemic context(30–32). Nonetheless, to date, there have been few studies demonstrating 119 feasibility or wider impact of such services in sub-Saharan Africa(33-35). The objective of this 120 study is to describe and assess the effect of a pragmatic COVID-19/TB and HIV integrated 121 122 screening and testing service model for adults and children older than 5 years in two remote referral hospitals in Lesotho. 123

124

125 Methods

126 Context

We implemented this screening and diagnostic model at the St Charles Missionary Hospital 127 Seboche and the Mokhotlong Government District Hospital, in the districts of Butha-Buthe and 128 Mokhotlong. These districts are characterized by mostly rural settings with an estimated 129 combined population of 250,000 people, who are mainly subsistence farmers, mine workers 130 or construction and domestic laborers who work in neighboring South Africa. Each district has 131 only one single mid-size town: Butha-Buthe with ca. 25,000 inhabitants and Mokhotlong with 132 ca. 10,000 inhabitants. The remaining population lives in villages scattered over a 133 mountainous area of 5,842 km². Health services in these two districts are provided through a 134 network of clinics and hospitals. In Butha-Buthe district health care is available thought 10 135 nurse-led rural health centers, 1 missionary hospital, and 1 governmental hospital. In 136 137 Mokhotlong services are available thought 9 nurse-led rural health centers, and 1 138 governmental hospital.

140 Integrated TB/COVID-19 and HIV screening and testing model

A nurse-led, multi-disease, integrated screening and diagnostic model was established, with the aim to provide same-day, one-stop shop diagnosis and clinical evaluation. After the diagnostic procedures were done, the nurses would manage cases themselves, or refer to other hospital staff, according to stablished clinical algorithms (figure 2). This service was continuously adapted to the needs and diagnostic standards, driven by a fast-changing context.

147 Screening, eligibility, and enrolment

Adults and children seeking health services, visitors, and staff attending daily work, were pre-148 screened by trained TB/COVID-19 lay screeners. Pre-screening took place in specially built 149 150 structures by the gates of the two hospitals and focused on the investigation of history of close contact with a COVID-19 case or the presence of at least one sign or symptom of TB or 151 COVID-19. The initial evaluation included: fever measured (\geq 38 °C, forehead or reported), 152 153 cough of any duration, pronounced tiredness, shortness of breath, sore throat, muscle or body 154 pain, diarrhoea, loss of taste/smell, weight loss, night sweat. We defined close contact with a (confirmed or probable) COVID-19 case, as a contact within one meter for more than 15 155 minutes, or direct physical contact with a (probable or confirmed) case, or direct care provided 156 to a patient with (probable or confirmed COVID-19) disease without using proper personal 157 158 protective equipment. A significant contact of TB was determined using the standard 159 definition(36). We defined positive pre-screening as the presence of at least one sign or symptom, or a history of close contact with a COVID-19 or TB case. People who pre-screened 160 positive and were 5 years or older, were referred to a nurse, who determined eligibility to enroll 161 162 in this diagnostic model, explained the testing procedures, and obtained informed consent.

Once the participant was enrolled, the nurse took medical history focusing on COVID-19, TB, and HIV, measured BMI, body temperature, and performed a clinical examination to assess the severity of respiratory symptoms. We defined mild, moderate and severe clinical presentation as follows: 1) mild disease included the presence of COVID-19 signs and

167 symptoms, without hypoxia or dyspnea; 2) moderate disease included the presence of signs and symptoms of pneumonia (fever, cough, dyspnea, tachypnoea) or an oxygen saturation ≤ 168 94%, with no signs of severe pneumonia; and 3) severe disease included the presence of at 169 least one of the following: altered mental status, oxygen saturation < 94% or signs of central 170 171 cyanosis, shortness of breath or difficulty breathing, fast breathing (5-9 y \ge 30 breaths/min; \geq 10 y \geq 20 breaths/min; and \geq 18 y \geq 22 breaths/min), systolic blood pressure <100 mmHg in 172 173 adults and general danger signs in children. For severely ill participants, the nurse referred 174 them to a physician in the hospital immediately after the clinical examination and patients 175 followed the integrated diagnostic procedures only if the physician judged that these would benefit them. Patients with mild or moderate symptoms at presentation remained in the study 176 and were offered all the clinical procedures. Enrolled participants had a digital posterior-177 anterior chest Xray done and analyzed using artificial intelligence-powered, computer-aided 178 179 detection software for TB (CAD4TB version 6; Delft Imaging Systems, the Netherlands). Those with a result score of 50 or above followed investigations for TB(37). 180

181 TB, COVID-19, and HIV diagnosis

Diagnosis of SARS-CoV-2 infection was done using RDTs or PCR, in different combinations 182 that varied along the implementation period, adapting to the enrolment of different studies, 183 184 and the evolving diagnostic recommendations for SARS-CoV-2 in Lesotho. We used the STANDARD Q COVID-19 Antigen test (SD Biosensor, Republic of Korea) with a nasal or a 185 nasopharyngeal swab, and PCR (ABI 7500 Real-Time PCR platform, Applied Biosystem, USA 186 and Xpert Xpress SARS-CoV-2 Cepheid, USA). All participants included in this study had at 187 188 least one nasopharyngeal SARS-CoV-2 RDT result. Participants who presented with presumptive TB symptoms or a CAD4TB score > 50 were requested to submit sputum for TB 189 diagnostic testing using the Xpert MTB/RIF Ultra (PCR GeneXpert, Cepheid, Sunnyvale, CA, 190 USA). Participants who were requested to submit sputum watched a video describing how to 191 192 produce a quality sputum before they attempted to produce the sample. For HIV diagnosis, 193 we followed standard of care in Lesotho, that included a first assessment using an HIV risk

screening tool to determine HIV testing eligibility. If participants were found to be high risk using the HIV testing screening tool, they were tested following the Lesotho HIV guidelines that used standard blood based RDTs(38). For the purpose of this study, we defined a COVID-197 19 case as an individual with a positive result in either RDT (nasopharyngeal or nasal swab) or PCR (nasopharyngeal swab). TB diagnosis was defined as a positive Xpert MTB/RIF Ultra result in sputum, and an HIV diagnosis was defined according to Lesotho standard testing algorithm.

201 Follow up after 28 days after testing

To measure the effect of this integrated multi-disease diagnostic service, in terms of linkage 202 203 to COVID-19 curative services, TB and HIV treatment initiation, all enrolled participants that 204 had at least one TB, COVID-19 (RDT or PCR) or HIV positive result, were followed up in a window of time around 28 days after enrolment. A study nurse attempted to contact each 205 206 participant or their next in kin, through a phone call. In the case of participants diagnosed with 207 COVID-19, we collected information on whether they were "healthy" (had recovered from symptoms, after the episode), "hospitalized" (still admitted due to the condition) or deceased. 208 For participants that were newly diagnosed with TB or HIV, we asked whether they had started 209 treatment after diagnosis and checked hospital records (TB and HIV registers) at the two 210 211 hospitals.

212 Ethical Consideration

All procedures were carried out in line with the ethical standards laid out in the Declaration of Helsinki(39). Participants that enroll in this diagnostic model received information on the clinical procedures in Sesotho and gave written informed consent and those who were illiterate gave consent by thumbprint and a witness signature. Parents or guardians of all participants below 18 years signed an informed consent form, while participants between 7 and 17 years additionally signed an assent form. This project was approved by the Lesotho Ministry of

Health Ethics Committee (ID 107-2020) and by the Ethic Committee Switzerland (EthikkommissioNordwest-und Zentralschweiz(EKNZ) AO_2020-00018).

221

222 Data collection and analysis

Clinical data was collected by trained nurses using the Open Data Kit (ODK) software(40). 223 224 Information that could not be obtained on the same day, such as Xpert MTB/RIF Ultra and 225 SARS-CoV-2 PCR results, was uploaded to ODK as soon as was available. Routine data quality checks were done regularly. To compare TB and HIV indicators across hospitals we 226 obtained data from the Lesotho District Health Information System 2(DHIS 2)(41). Information 227 about social restrictions, COVID-19 policies modification, and COVID-19 national response in 228 Lesotho was compiled using the Lesotho Ministry of Health sources. Descriptive statistics 229 were used to characterize the study sample. Median and interguartile range (IQR) were 230 calculated to describe continuous variables, and frequencies and percentages for categorical 231 232 variables. Statistical analysis was performed using Stata (version 16.1, College Station, Tex: StataCorp LP, 2007). 233

234 Results

235 Of the 179160 adults and children that were pre-screened, a total of 6623 (37%) had at least one COVID-19 symptom or history of close contact with a COVID-19 or TB case. Amongst 236 237 those who pre-screened positive, a total of 4371 (66%) were enrolled in the integrated TB/COVID-19/HIV testing procedures. The remaining 2252 (34%) participants that did not 238 enrolled despite presenting symptoms were: 1) children below 5 years, 2) unaccompanied 239 children between the age of 7 and 17 years, 3) patients presenting in the weekends, when the 240 service was not available, 4) patients with severe symptoms that required immediate medical 241 242 attention, or 5) people who refuse to enroll in this service. Table 2 provides an overview of the 243 baseline characteristics of enrolled participants. A total of 2468 (61,7%) were adult women and 369 (8.4%) were children and adolescents between the age of 5 and 17 years. Most of 244

245 them presented with at least one symptom, most commonly cough, or pronounced tiredness. 246 The median time from symptoms onset was 3 (IQR 2 -7) days, more than 98% presented with 247 mild or moderate symptoms and had an oxygen saturation \geq 95%. A total of 1768 (44.1%) adults had overweight or obesity (BMI ≥25 Kg/m2), 1058 (27.8%) had one elevated blood 248 249 pressure measurement (≥140/90 mmHg), and 321 (8.0%) reported current tobacco use. A 250 total of 125 (3.7%) adults and 2 (0.6%) children reported a recent TB contact, while 111 (3.3%) 251 adults and 6 (1.9%) children reported a recent COVID-19 contact. A total of 814 adults (20.3%) 252 and 28 children (7.6%) reported to live with HIV.

253 Integrated COVID-19/TB and HIV screening and testing model

254 A summary of the diagnostic results is available in table 3. In terms of SARS-CoV-2 testing, a 255 total of 4355, 2421 and, 2664 nasopharyngeal RDT, nasal RDT, and nasopharyngeal PCR tests were done. With regards to TB investigations, a total of 4371 chest x-rays were 256 257 performed, and overall, 884 (29.3%) participants had a CAD4TB score > 50. For the 2419 258 participants who were eligible for sputum collection, 1454 samples were collected and tested with Xpert MTB/RIF Ultra. Most common reasons for not collecting sputum included patient 259 refusing (377; 15,8%) or unable to produce a sample (263; 10.8%). A total of 104 people was 260 tested for HIV. Overall, a total of 458 new diagnoses were made, of which 383, 51 and 24 261 262 were COVID-19, TB, and HIV cases, respectively (table 3). Newly found cases were mainly diagnosed among adults. Only 16 (4.3%) of the COVID-19 cases and 1 (1%) of the TB cases 263 264 were diagnosed in children and adolescent participants, and this model did not find any new HIV diagnosis amongst them. 265

With regards to the clinical outcomes after four weeks of diagnosis, of the 458 people who were diagnosed with either COVID-19, TB or HIV, a total of 321 (82.9%) participants, or their relatives could be reached. Of those, 304 (94.7%) reported that they were healthy, whereas 5 (1.3%) reported to be ill or hospitalized (four people diagnosed with COVID-19 and one person who was HIV positive). We recorded 12 (3.7%) participants who died in this period, however we did not record the possible causes of death. Of the individuals that were newly diagnosed

with HIV or TB, a total of 18/24 (75.0%) and 46/51 (90.1%) had started ART and TB treatment
respectively, during this period (table 3).

The yield of this integrated testing model in terms of aditional HIV, TB, and COVID-19 274 diagnosis across periods of different COVID-19 incidence is displayed in figure 3. Periods 1 275 and 4 (end of 2020 to mid-February 2021, and end of November 2021 to end of February 276 2022), are characterized by high SARS-COV-2 RDT positivity rates (20-40%), during very 277 short periods of time (distinct COVID-19 waves). Periods 3 and 5 (mid-June to end of 278 November 2021, and end of February to end of August 2022), are marked by lower SARS-279 280 COV-2 RDT positivity rates across longer periods of time, indicating ongoing, low level of community transmission. During period 2 (mid-February 2021 to Mid-June 2021), there were 281 almost no COVID-19 cases diagnosed at our sites. During periods of high COVID-19 incident 282 cases (1 and 4), when study staff had to cope with a larger number of enrolled participants, 283 284 the number of TB and HIV additional cases found was irregular. Whereas the periods of lower COVID-19 incident cases allowed for a higher number of new TB and HIV diagnosis. 285

286 Comparison performance of TB and HIV services with similar hospitals

Figure 4 shows trends of HIV and TB new notifications, as well as the ART initiations, reported 287 288 in six hospitals Lesotho during the period of October 2020 to March 2022, using the Lesotho 289 DHIS-2 reporting system. Portrayed sites include the two study sites (Seboche Mission Hospital and Mokhotlong Hospital), compared to Paray, St. James, Ntseke, and Tellebong 290 hospitals, where COVID-19 testing was conducted but not integrated with TB and HIV 291 292 services. All hospitals maintained HIV and TB services similarly during this period and the 293 Seboche and Mokhotlong hospitals, where this diagnostic model was implemented, seemed 294 to perform quite similarly.

295

296 Discussion

297 This observational study aimed to describe and assess the impact of an integrated COVID-298 19, TB and HIV screening and testing service model in two hospitals in rural Lesotho, during 299 the period between December 2020 and August 2022. Our setting was characterized by an overall low incidence of COVID-19 cases, a volatile context, and social restrictions in 300 301 continuous revision. Nonetheless, this service operated during two distinct COVID-19 waves and two other periods when COVID-19 incident cases were continuously low. This pragmatic 302 303 diagnostic service model provided integrated diagnostic services to 4.371 adults and children. 304 who most frequently presented with non-severe symptoms, and previous contact with a TB or 305 COVID-19 case was unfrequently reported. The overall diagnostic yield, including COVID-19, 306 TB, and HIV, was 458 new cases, most frequently found in adults; only 17 (3.7%) of them 307 happened in children and adolescents.

It is almost certain that in this study we underestimate the number of COVID-19 and TB cases 308 309 diagnosed. In the case of COVID-19 cases, a PCR test was used as the gold standard for diagnosis during most part of 2021. Later on, diagnosis was based on the result of the SARS-310 CoV-2 STANDARD Q COVID-19 Ag test, that has shown relatively low diagnostic 311 performance in our setting (42). Anecdotically, a number of the 2252 (34%) eligible adults and 312 313 children that presented with symptoms but did not enroll in this service model despite being 314 eligible, were still tested for COVID-19 by the study staff, especially in periods were hospital health staff in other departments was scarce, however, these individuals are not included in 315 316 this analysis. With regards to the definition of TB case in this study, we report only positive Xpert MTB/RIF Ultra results in the sputum of participants, from whom we obtained a sample. 317 In our case, sputum samples could not be obtained for one third of the participants, mainly 318 due to refusals or inability to produce them. Additionally, for this analysis, we did not consider 319 a clinical TB diagnosis made by clinicians once a symptomatic patient was referred to further 320 321 evaluation by hospital staff.

To interpret these findings, it is also important to consider broader contextual factors that played a role. One of them is related to the variation of circulating SARS-CoV-2 virus (Omicron

variant) and the lower diagnostic sensitivity observed using RDTs(43,44). In our setting, this could have led to a lower detection or cases in symptomatic people seeking services. A second factor could be related to the fluctuating access to hospital services. It is probable that the changes imposed by the social restrictions, the availability of service providers (themselves ill, in quarantine or isolated due to a recent contact), or the fear to acquire a COVID-19 infection in the hospital, were important deterrents for symptomatic people to use hospital services.

331 Of the 321 (82.9%) participants that were successfully reached after four weeks of the 332 diagnosis, 304 (94.7%), 18/24 (75%), and 46/53 (86.8%) were in good health, had started ART and TB treatment respectively during this period. We recorded 12 (3.6%) participants 333 deaths, however, around one in six participants with a diagnosis could not be contacted in the 334 follow up period, therefore these results need to be interpreted with caution. Using the total 335 336 number of 4371 enrolled participants as a benchmark, we calculate that we found one SARS-CoV-2 rapid antigen positive per 11 people screened, one Xpert MTB/RIF Ultra positive test 337 per 85 people screened, and 1 HIV new diagnosis was found per 182 people screened. 338

Surprisingly, we found no clear evidence to suggest that this resource-intense screening and 339 testing model had a significantly different impact in sustaining access to TB and HIV diagnostic 340 341 and treatment services, compared to similar hospitals in Lesotho, where this diagnostic model was not in place, when referring to the Lesotho TB and HIV DHIS-2 reports. During the 342 analyzed period of October 2020 to March 2022, the number of HIV new diagnosis, ART 343 initiations, and TB case notifications in the six hospitals seem guite similar. Additionally, the 344 results from our study suggest that this diagnostic model had little impact on pediatric and 345 346 adolescent COVID-19, TB and HIV case finding in participants who were between the age of 347 5 and 18 years. On the other hand, the overall TB and HIV linkage to care rates within four 348 weeks of diagnosis were higher than reported in similar experiences(45–48), however when 349 comparing to global targets, this model fell short in ART initiation rates (75% vs 95%), and met 350 the TB treatment initiation target (90% vs. 90%)(49,50).

351 As the COVID-19 pandemic surged, and lockdowns led to the cancellation of essential health 352 services, global health actors advocated to adapt services that integrated TB, HIV and COVID-353 19 activities in sub-Saharan Africa (29,42–44). This established an emerging body of evidence 354 that evaluates the experiences and successes in the integration of services. A study in 355 Uganda, using gualitative methods(34), reported that facilitators to integrate COVID-19 and 356 TB services included availability of focal health workers who were solely responsible for this task, and availability of standard procedures and data collection tools. In this setting, 357 358 inconsistent supply of protective gear and fear of contracting COVID-19 decreased the 359 efficiency of the service. A study in Ethiopia reported a sharp reduction of TB service indicators in Addis Ababa, partially mitigated with the use of digital health technology to screen for TB, 360 however, their results were not conclusive, due to lack of patient-level data(33). Another 361 similar experience in Niger and Guinea(54), found that out of the 863 individuals enrolled, 61 362 363 (7%) tested positive for COVID-19 and 43 (4.9%) were diagnosed with TB. These results are comparable to our COVID-19 notifications in Lesotho (383, 8.8%), however, the investigators 364 in Niger and Guinea found a higher number of TB cases than in our setting [35 (4.6%) in 365 Guinea, 8 (7.6%) in Niger, and 51 (1.1%) in Lesothol. Reports of pragmatic integrated 366 367 experiences aiming to sustain HIV testing and linkage to treatment amid the COVID-19 epidemic across sub-Saharan Africa are very scarce. A systematic review evaluating the 368 impact of the COVID-19 pandemic on accessing HIV services in South Africa, and an 369 evaluation of performance of services in primary health clinics (55,56) revealed that there were 370 significant decreases in HIV testing, positive HIV tests, and ART initiation at public health 371 facilities. However, the private facilities had maintained their activity similarly to pre-pandemic 372 levels, confirming a disparity in health access between the private and public sectors. In our 373 374 service, the routine use of the HIV testing screening tool targeted individuals who were most at risk of a recent infection and yet, one in five people tested positive for HIV. However, it is 375 important to note that in our setting performing HIV testing depended greatly on the availability 376 of time that the study nurses had, while being burdened with other tasks. In periods of sharp 377 COVID-19-related overload, created by an increase of influx of individuals looking to be tested, 378

379 participants who were also eligible for HIV testing were referred to the routine hospital HIV testing services. This was a result of an effort to maintain the function of the COVID-19 380 diagnostic services and the quality of the HIV testing service. This typically happened in a 381 different hospital department and could have decreased the efficiency to find new HIV cases. 382 383 Similarly to other published studies in sub-Saharan Africa and other regions of the world(33-35.54.57–59), our integrated screening and diagnostic model proved to be a resource 384 385 intensive service, that had to adapt to contextual factors continuously. To ensure availability 386 and continuity of the service, we made significant investments in the deployment, protection, 387 training, and support of health staff.

Our study had various limitations. A major weakness is that we report on a hospital-based 388 screening and testing model, that served the population that voluntarily reached and enrolled 389 in the service. Therefore, our results refer to a selected population. By the end of 2021, SARS-390 391 CoV-2 ag-RDTs became available at community level, through local retailers and primary health clinics. As capacity for rapid testing for COVID-19 expanded, the population living in 392 these districts could choose where and how receive this service. Secondly, complementing 393 394 our study with gualitative approaches could have increased the efficiency, and acceptability of 395 the integrated diagnostic service, and explored the level and consequences of stigma related to COVID-19 in our setting. However, these aspects were explored from the perspective of 396 397 the community in the two districts and will be reported in other studies. Lastly, an economic 398 analysis of this model could shed light on important questions related to health system-related costs and patients-related costs. Despite these limitations, this is the first study evaluating the 399 400 effect of an integrated, COVID-19/TB and HIV diagnostic model in sub-Saharan Africa, covering a period of 22 months and reporting on disaggregated characteristics and outcomes 401 in adults and children above 5 years. 402

403

404 Conclusion

This study shows that integrated testing for TB/COVID-19 and HIV is feasible in resourceconstraint, routine programmatic settings. Our findings provide information to support health system managers and policy makers in the design of services that integrate COVID-19 aspects. Continuous surveillance of COVID-19 incident cases, availability of health staff, and routine monitoring of diagnostic yields are important aspects to adapt these services and find

- 410 efficiencies in such rapid-evolving contexts.
- 411
- 412

413 **Declarations**

414

415 Ethics approval and consent to participate

This project was approved by the Lesotho Ministry of Health Ethics Committee (ID 107-2020)
and by the Ethic Committee Switzerland (EthikkommissioNordwest-und Zentralschweiz
(EKNZ) AO_2020-00018)

- 419 **Consent for publication**
- 420 All authors consent to the publication of this manuscript.
- 421

422 Availability of data and materials

423 All data generated or analyzed during this study are included in this published article [and its 424 supplementary information files]. All articles used for the review are in the references section.

- 425
- 426 Competing interests
- 427 None declared
- 428
- 429 Funding

Funding was provided by the Botnar Research Centre for Child Health (to Dr. Klaus Reither)in June 2020.

432

433 Author Contributions

BK, KR, and LGF conceptualized the study and design. BK, MB, RME, TG performed references screening, data collection and summarization. BK, KR, and LGF drafted the manuscript. All authors reviewed the results and approved the final version of the manuscript.

443 References

- Kendzerska T, Zhu DT, Gershon AS, Edwards JD, Peixoto C, Robillard R, et al. The Effects of the 444 1. Health System Response to the COVID-19 Pandemic on Chronic Disease Management: A 445 446 Narrative Review. Risk Manag Healthc Policy. 2021;14:575-84.
- 447 Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19 2. 448 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021 Mar 449 16;11(3):e045343.
- 450 3. Arsenault C, Gage A, Kim MK, Kapoor NR, Akweongo P, Amponsah F, et al. COVID-19 and resilience of healthcare systems in ten countries. Nat Med. 2022 Jun;28(6):1314–24. 451
- 452 4. Third round of the global pulse survey on continuity of essential health services during the 453 COVID-19 pandemic: November - December 2021: interim report, 7 February 2022 - World | ReliefWeb [Internet]. [cited 2022 Dec 2]. Available from: 454
- https://reliefweb.int/report/world/third-round-global-pulse-survey-continuity-essential-health-455 456 services-during-covid-19
- 457 5. World Health Organization. Maintaining essential health services: operational guidance for the 458 COVID-19 context. World Health Organization. 2020; (June):55.
- 459 6. PATH. Essential health services during and after COVID-19: A sprint analysis of disruptions and 460 responses across six countries. 2020;(December):26.
- 461 Global Tuberculosis Report 2022 [Internet]. [cited 2022 Dec 1]. Available from: 7. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-462 report-2022 463
- 8. HIV and COVID-19 [Internet]. [cited 2022 Dec 1]. Available from: 464 https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/covid-19 465
- 466 Nachega J, Seydi M, Zumla A. The late arrival of coronavirus disease 2019 (COVID-19) in Africa: 9. Mitigating pan-continental spread. Clinical Infectious Diseases. 2020;71(15):875-8. 467
- 468 10. Holtzman CW, Godfrey C, Ismail L, Raizes E, Ake JA, Tefera F, et al. PEPFAR's Role in Protecting 469 and Leveraging HIV Services in the COVID-19 Response in Africa. Current HIV/AIDS Reports. 470 2022;19(1):26-36.
- 11. Tessema GA, Kinfu Y, Dachew BA, Tesema AG, Assefa Y, Alene KA, et al. The COVID-19 pandemic 471 472 and healthcare systems in Africa: A scoping review of preparedness, impact and response. BMJ 473 Global Health. 2021;6(12):1-14.
- 474 12. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-475 19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series 476 analysis. The Lancet HIV [Internet]. 2021 Mar 1 [cited 2022 Dec 1];8(3):e158–65. Available from: 477 https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30359-3/fulltext
- 478 13. Population, total - Lesotho | Data [Internet]. [cited 2022 Dec 14]. Available from: 479 https://data.worldbank.org/indicator/SP.POP.TOTL?locations=LS

- 480 14. TB profile [Internet]. [cited 2022 Nov 25]. Available from:
- 481 https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&lan= 482 %22EN%22&iso2=%22LS%22
- 15. Schwitters A, McCracken S, Frederix K, Tierney R, Koto M, Ahmed N, et al. High HIV prevalence 483 484 and associated factors in Lesotho: Results from a population-based survey. PLOS ONE [Internet]. 485 2022 Jul 28 [cited 2022 Nov 25];17(7):e0271431. Available from:
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271431 486
- 16. Lesotho [Internet]. [cited 2022 Dec 11]. Available from: 487
- 488 https://www.unaids.org/en/regionscountries/countries/lesotho
- 489 17. COVID-19 Preparedness in Lesotho [Internet]. THET. [cited 2022 Nov 26]. Available from: 490 https://www.thet.org/case-studies/covid-19-preparedness-in-lesotho/
- 491 18. Family planning uptake drops in Lesotho due to COVID-19 restrictions, analysis shows - Lesotho 492 | ReliefWeb [Internet]. [cited 2022 Nov 26]. Available from:
- 493 https://reliefweb.int/report/lesotho/family-planning-uptake-drops-lesotho-due-covid-19-494 restrictions-analysis-shows
- 495 19. Sanders JE, Chakare T, Mapota-Masoabi L, Ranyali-Otubanjo M, Ramokhele MM, Rozario A, et 496 al. National hospital readiness for COVID-19 in Lesotho: Evidence for oxygen ecosystem 497 strengthening [Internet]. medRxiv; 2021 [cited 2022 Nov 26]. p. 2021.04.27.21256199. Available 498 from: https://www.medrxiv.org/content/10.1101/2021.04.27.21256199v1
- 499 20. Nyangu I, Ramathebane M. Perceptions of Healthcare Professionals on COVID-19 in Lesotho: A 500 Cross-Sectional Survey. Journal of Biosciences and Medicines [Internet]. 2022 Jan 29 [cited 2022] 501 Nov 26];10(2):39–50. Available from:
- 502 http://www.scirp.org/Journal/Paperabs.aspx?paperid=115129
- 503 21. Lesotho-Humanitarian-SitRep-June-2021.pdf [Internet]. [cited 2022 Dec 11]. Available from: 504 https://www.unicef.org/media/104171/file/Lesotho-Humanitarian-SitRep-June-2021.pdf
- 505 22. Lesotho: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data [Internet]. 506 [cited 2022 Nov 26]. Available from: https://covid19.who.int
- 507 23. Release AP. Lesotho Moves to Green Code Colour Stage [Internet]. [cited 2022 Nov 26]. 508 Available from: https://www.zawya.com/en/press-release/africa-press-releases/lesotho-moves-509 to-green-code-colour-stage-g26m14mn
- 24. LESOTHO MOVES TO BLUE COLOUR CODING STAGE Government Of Lesotho [Internet]. [cited 510 511 2022 Nov 26]. Available from: https://www.gov.ls/lesotho-moves-to-blue-colour/
- 512 25. Lesotho 2020.08.24 Regulation Public-Health-COVID-19-Risk-Determination-and-Mitigation-513 Measures-No.-3-Regulations-2020_EN_.pdf [Internet]. [cited 2022 Nov 26]. Available from: https://covidlawlab.org/wp-content/uploads/2022/01/Lesotho_2020.08.24_Regulation_Public-514 Health-COVID-19-Risk-Determination-and-Mitigation-Measures-No.-3-Regulations-515 2020_EN_.pdf 516
- 26. Public-Health-Covid-19-risk-Determination-and-Mitigation-Measure-No.5-Amendment-517 518 Regulations-2022.pdf [Internet]. [cited 2022 Nov 26]. Available from:
- 519 https://kleingeldmayet.co.ls/wp-content/uploads/2022/01/Public-Health-Covid-19-risk-
- 520 Determination-and-Mitigation-Measure-No.5-Amendment-Regulations-2022.pdf

- 521 27. kleingeld. Lesotho Covid-19 Resource Portal – Adjusted Blue Colour Code [Internet]. Kleingeld & 522 Mayet. 2022 [cited 2022 Nov 26]. Available from: https://kleingeldmayet.co.ls/lesotho-covid-19-523 resource-portal-adjusted-blue-colour-code/
- 28. NNN. Lesotho moves to green code color stage [Internet]. NNN. 2022 [cited 2022 Nov 26]. 524 525 Available from: https://nnn.ng/lesotho-moves-to-green-code-color-stage/
- 526 29. MistraL: Mitigation Strategies for Communities With COVID-19 Transmission in Lesotho Using 527 Artificial Intelligence on Chest X-rays and Novel Rapid Diagnostic Tests – BRCCH [Internet]. [cited 2022 Nov 26]. Available from: https://brc.ch/research/mistral/ 528
- 529 30. Ruhwald M, Hannay E, Sarin S, Kao K, Sen R, Chadha S. Considerations for simultaneous testing 530 of COVID-19 and tuberculosis in high-burden countries. The Lancet Global Health [Internet]. 531 2022 Apr 1 [cited 2022 Nov 25];10(4):e465–6. Available from:
- 532 https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(22)00002-X/fulltext
- 533 31. MacLean EL, Villa-Castillo L, Ruhwald M, Ugarte-Gil C, Pai M. Integrated testing for TB and COVID-19. Med (N Y) [Internet]. 2022 Mar 11 [cited 2022 Nov 25];3(3):162-6. Available from: 534 535 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831149/
- 536 32. Holtzman CW, Godfrey C, Ismail L, Raizes E, Ake JA, Tefera F, et al. PEPFAR's Role in Protecting 537 and Leveraging HIV Services in the COVID-19 Response in Africa. Curr HIV/AIDS Rep [Internet]. 538 2022 [cited 2022 Nov 25];19(1):26–36. Available from: 539 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724594/
- 540 33. Arega B, Negesso A, Taye B, Weldeyohhans G, Bewket B, Negussie T, et al. Impact of COVID-19 541 pandemic on TB prevention and care in Addis Ababa, Ethiopia: a retrospective database study. 542 BMJ Open [Internet]. 2022 Feb 8 [cited 2022 Nov 25];12(2):e053290. Available from: 543 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829833/
- 544 34. Semitala FC, Katwesigye R, Kalibbala D, Mbuliro M, Opio R, Owachi D, et al. Integration of 545 COVID-19 and TB screening in Kampala, Uganda - Healthcare provider perspectives. Res Sq [Internet]. 2022 Jun 7 [cited 2022 Nov 25];rs.3.rs-1448831. Available from: 546 547 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196119/
- 548 35. Njau A, Kimeu J, Gohil J, Nganga D. Informing healthcare operations with integrated pathology, 549 clinical, and epidemiology data: Lessons from a single institution in Kenya during COVID-19 550 waves. Front Med (Lausanne). 2022;9:969640.
- 36. Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, et al. Duration of Exposure Among 551 552 Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. 553 Clinical Infectious Diseases [Internet]. 2020 Oct 23 [cited 2022 Dec 15];71(7):1627–34. Available 554 from: https://doi.org/10.1093/cid/ciz1044
- 555 37. Qin ZZ, Ahmed S, Sarker MS, Paul K, Adel ASS, Naheyan T, et al. Tuberculosis detection from 556 chest x-rays for triaging in a high tuberculosis-burden setting: an evaluation of five artificial 557 intelligence algorithms. The Lancet Digital Health [Internet]. 2021 Sep 1 [cited 2022 Dec 558 11];3(9):e543–54. Available from: https://www.thelancet.com/journals/landig/article/PIIS2589-559 7500(21)00116-3/fulltext
- 560 38. Linkages across the Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES): 561 Country Resources [Internet]. FHI 360. [cited 2022 Dec 2]. Available from:

562 https://www.fhi360.org/resource/linkages-across-continuum-hiv-services-key-populations-563 affected-hiv-linkages-country 564 39. WMA - The World Medical Association-WMA Declaration of Helsinki – Ethical Principles for 565 Medical Research Involving Human Subjects [Internet]. [cited 2022 Nov 25]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-566 567 research-involving-human-subjects/ 568 40. Open Data Kit [Internet]. Open Data Kit. 2018 [cited 2022 Dec 1]. Available from: 569 https://opendatakit.org/ 41. Improving DHIS2 Integration for Lesotho's Health Information Ecosystem - Implementation -570 571 Implémentation / Interoperability [Internet]. DHIS2 Community. 2022 [cited 2022 Nov 25]. Available from: https://community.dhis2.org/t/improving-dhis2-integration-for-lesothos-health-572 573 information-ecosystem/47463 574 42. Labhardt ND, Fernández LG, Katende B, Muhairwe J, Bresser M, Amstutz A, et al. Head-to-head comparison of nasal and nasopharyngeal sampling using SARS-CoV-2 rapid antigen testing in 575 576 Lesotho [Internet]. medRxiv; 2022 [cited 2022 Dec 2]. p. 2021.12.29.21268505. Available from: 577 https://www.medrxiv.org/content/10.1101/2021.12.29.21268505v1 578 43. Use of Rapid Antigen Tests during the Omicron Wave [Internet]. Ontario COVID-19 Science 579 Advisory Table. [cited 2022 Dec 13]. Available from: https://covid19-580 sciencetable.ca/sciencebrief/use-of-rapid-antigen-tests-during-the-omicron-wave/ 581 44. Bekliz M, Adea K, Puhach O, Perez-Rodriguez F, Marques Melancia S, Baggio S, et al. Analytical 582 Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting Rapid Tests for Omicron-BA.1 583 Variant. Microbiology Spectrum [Internet]. 2022 Aug 8 [cited 2022 Dec 13];10(4):e00853-22. 584 Available from: https://journals.asm.org/doi/10.1128/spectrum.00853-22 585 45. Chawla KS, Kanyama C, Mbewe A, Matoga M, Hoffman I, Ngoma J, et al. Policy to practice: 586 impact of GeneXpert MTB/RIF implementation on the TB spectrum of care in Lilongwe, Malawi. 587 Transactions of The Royal Society of Tropical Medicine and Hygiene [Internet]. 2016 May 1 588 [cited 2022 Dec 2];110(5):305–11. Available from: https://doi.org/10.1093/trstmh/trw030 589 46. Shapiro AE, van Heerden A, Schaafsma TT, Hughes JP, Baeten JM, van Rooyen H, et al. 590 Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in 591 South Africa and Uganda. J Int AIDS Soc [Internet]. 2018 Jan 30 [cited 2022 Dec 2];21(1):e25065. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810338/ 592 593 47. Katende B, Esterhuizen TM, Dippenaar A, Warren RM. Rifampicin Resistant Tuberculosis in 594 Lesotho: Diagnosis, Treatment Initiation and Outcomes. Sci Rep [Internet]. 2020 Feb 5 [cited 595 2022 Dec 2];10(1):1–8. Available from: https://www.nature.com/articles/s41598-020-58690-4 596 48. Mabote N, Mamo M, Nsakala B, Lanje S, Mwanawabene NR, Katende B. Linkage to care and 597 treatment outcomes for patients diagnosed with drug-susceptible tuberculosis using Xpert 598 MTB/RIF assay in Thaba-Tseka district in Lesotho. IJID Regions [Internet]. 2022 Dec 1 [cited 2022 599 Dec 2];5:33–8. Available from: https://www.sciencedirect.com/science/article/pii/S2772707622001047 600 601 49. LESOTHO TB Dashboard [Internet]. [cited 2022 Nov 26]. Available from: 602 https://www.stoptb.org/static_pages/LSO_Dashboard.html

medRxiv preprint doi: https://doi.org/10.1101/2022.12.20.22283748; this version posted December 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY 4.0 International license .
- 603 50. Lesotho [Internet]. [cited 2022 Nov 26]. Available from:
- https://www.unaids.org/en/regionscountries/countries/lesotho 604
- 605 51. PCB48 Thematic Segment Background Note EN.rev2 .pdf [Internet]. [cited 2022 Nov 25]. 606 Available from:
- https://www.unaids.org/sites/default/files/media_asset/PCB48_Thematic_Segment_Backgroun 607 608 d_Note_EN.rev2_.pdf
- 609 52. WHO supports government to integrate COVID-19 case finding into TB surveillance activities.
- [Internet]. WHO | Regional Office for Africa. [cited 2022 Nov 25]. Available from: 610
- 611 https://www.afro.who.int/news/who-supports-government-integrate-covid-19-case-finding-tb-612 surveillance-activities
- 613 53. Strategic considerations for mitigating the impact of COVID-19 on key-population-focused HIV 614 programs [Internet]. [cited 2022 Dec 2]. Available from:
- 615 https://www.unaids.org/en/resources/documents/2020/key-populations-strategicconsiderations-covid19 616
- 617 54. Magassouba AS, Bassirou SM, Touré AA, Diallo BD, Alphazazi S, Cissé D, et al. Evaluating the 618 Effectiveness of a Novel Systematic Screening Approach for Tuberculosis among Individuals 619 Suspected or Recovered from COVID-19: Experiences from Niger and Guinea. Tropical Medicine and Infectious Disease [Internet]. 2022 Sep [cited 2022 Dec 13];7(9):228. Available from: 620 621 https://www.mdpi.com/2414-6366/7/9/228
- 55. Dorward J, Khubone T, Gate K, Ngobese H, Sookrajh Y, Mkhize S, et al. The impact of the COVID-622 623 19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series 624 analysis. Lancet HIV. 2021 Mar;8(3):e158-65.
- 625 56. Jardim CGR, Zamani R, Akrami M. Evaluating the Impact of the COVID-19 Pandemic on Accessing 626 HIV Services in South Africa: A Systematic Review. Int J Environ Res Public Health [Internet]. 2022 Sep 21 [cited 2022 Nov 25];19(19):11899. Available from: 627
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9565529/ 628
- 629 57. Khobragade RN, Murthy N, Aloysius S, Surendran D, Rakesh PS, Balakrishnan S. Experience of integrated screening and testing for TB and COVID19 from Kerala, India. Public Health Pract 630 631 (Oxf) [Internet]. 2021 Oct 2 [cited 2022 Nov 25];2:100198. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486580/ 632
- 633 58. Malik AA, Hussain H, Maniar R, Safdar N, Mohiuddin A, Riaz N, et al. Integrated Tuberculosis and 634 COVID-19 Activities in Karachi and Tuberculosis Case Notifications. Trop Med Infect Dis [Internet]. 2022 Jan 15 [cited 2022 Nov 25];7(1):12. Available from: 635
- 636 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778721/
- 637 59. Muñiz-Salazar R, Le T, Cuevas-Mota J, González-Fagoaga JE, Zapata-Garibay R, Ruiz-Tamayo PS, et al. Impact of COVID-19 on tuberculosis detection and treatment in Baja California, México. 638 639 Front Public Health [Internet]. 2022 Jul 22 [cited 2022 Nov 25];10:921596. Available from: 640 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356343/
- 641

642